GLP-1 Analogs and SGLT2 Inhibitors Do Not Increase Risk of Bullous Pemphigoid

被引：2
|
作者：
Varpuluoma, Outi [1 ,2 ,3 ]
Jokelainen, Jari [4 ,5 ]
Huilaja, Laura [1 ,2 ,3 ]
Tasanen, Kaisa [1 ,2 ,3 ]
机构：
[1] Univ Oulu, PEDEGO Res Unit, Fac Med, Oulu, Finland
[2] Univ Oulu, Oulu Univ Hosp, Dept Dermatol, Oulu, Finland
[3] Univ Oulu, Oulu Univ Hosp, Med Res Ctr, Oulu, Finland
[4] Univ Oulu, Infrastruct Populat Studies, Fac Med, Oulu, Finland
[5] Oulu Univ Hosp, Unit Gen Practice, Oulu, Finland
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2021年 / 141卷 / 12期
基金：
芬兰科学院;
关键词：
D O I：
10.1016/j.jid.2021.05.015
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：2969 / +
页数：5
相关论文
共 50 条
  • [1] Role of SGLT2 Inhibitors and GLP-1 Analogs in Cardiovascular Risk Reduction in Type 2 Diabetes
    Rashed, Mostafa Hamdy
    Dauyoumor, Tonbra Deborah
    Corney, Sarah
    Konono, Kimberly
    Joubert, Nadia
    Mohamed, Marwa
    Sukhoo-Pertab, Michon
    Makhomisane, Mobowa
    Njeri, Irene
    Mwita, Julius
    Sefen, Mariam
    Mohamed, Khadija
    Whiley, Nicolette
    WORLD FAMILY MEDICINE, 2021, 19 (12): : 119 - 128
  • [2] GLP-1 RA and SGLT2 Inhibitors In Harmony for Organ Protection
    Aroda, Vanita R.
    Billings, Liana K.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (06) : 526 - 528
  • [3] SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?
    Cervantes, Carlos Escobar
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (08): : 507 - 508
  • [4] GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?
    Nauck, Michael A.
    Meier, Juris J.
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (12): : 963 - 964
  • [5] SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination
    De Block, Christophe
    LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (05): : 349 - 352
  • [6] Positioning of GLP-1 receptor agonists and SGLT2 inhibitors: what do the guidelines say in diabetes?
    Darmon, P.
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2023, 27 (02): : 62 - 65
  • [7] SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
    Brown, Emily
    Heerspink, Hiddo J. L.
    Cuthbertson, Daniel J.
    Wilding, John P. H.
    LANCET, 2021, 398 (10296): : 262 - 276
  • [8] Comparative Effectiveness of SGLT2 Inhibitors vs. GLP-1 Agonists
    Poonawalla, Insiya
    Bowe, Andy
    Tindal, Michael
    Meah, Yunus A.
    Schwab, Phil
    DIABETES, 2020, 69
  • [9] In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality
    Kelsey, Michelle D.
    Newby, L. Kristin
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (03) : JC26 - JC26
  • [10] Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
    Goncalves, Edison
    Bell, David S. H.
    DIABETES THERAPY, 2018, 9 (03) : 919 - 926
12345